Leigh E. Efird, PharmD, MPH

Articles by Leigh E. Efird, PharmD, MPH

Prescribing Patterns of Novel Anticoagulants Within a Statewide Multispecialty Practice

ByLeigh E. Efird, PharmD, MPH,Jessica Chasler, PharmD,G. Caleb Alexander, MD, MS,Maura McGuire, MD

June 21st 2016

While warfarin remains the most commonly prescribed anticoagulant, novel anticoagulant use appears to be increasing especially among cardiologists. With new indications for these agents, uptake in prescribing by primary care providers is likely to increase.

Latest Updated Articles

Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 12th 2025 | Updated: June 16th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 10th 2025 | Updated: June 12th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 2nd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: June 3rd 2025 | Updated: June 11th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: May 30th 2025 | Updated: June 5th 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
Published: April 18th 2025 | Updated: April 21st 2025

Leigh E. Efird, PharmD, MPH

Articles by Leigh E. Efird, PharmD, MPH

Prescribing Patterns of Novel Anticoagulants Within a Statewide Multispecialty Practice

Latest Updated Articles

Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights

IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma

Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma

IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma

Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety

FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab